Limited ERG11 Mutations Identified in Isolates of Candida auris Directly Contribute to Reduced Azole Susceptibility
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Multiple Erg11 amino acid substitutions were identified in clinical isolates of Candida auris originating from India and Colombia. Elevated azole MICs were detected in Saccharomyces cerevisiae upon heterologous expression of C. auris ERG11 alleles that encoded for Y132F or K143R substitutions; however, expression of alleles encoding I466M, Y501H, or other clade-defined amino acid differences yielded susceptible MICs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, in Candida auris, ERG11 polymorphisms as well as an increased number of ERG11 gene copies are thought to be responsible for its largely intrinsic azole resistance37–40”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in ERG11 also contribute to reduced azole susceptibility in the emerging fungal pathogen C. auris12–15, with a recent study highlighting a previously unreported substitution in Erg11 (F444L) identified in azole-resistant clade IV clinical isolates that has not been previously described in other reports15.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“heterologous expression of C. auris ERG11 alleles carrying mutations encoding either the Y132F or K143R amino acid substitution on a low-copy-number episomal plasmid was observed to decrease fluconazole susceptibility in a haploid strain of Saccharomyces cerevisiae (13).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [13]
In the citing paper
“Heterologous expression of C. auris ERG11 alleles carrying the mutations leading to the Y132F and K143R substitutions on a low copy number episomal plasmid in Saccharomyces cerevisiae revealed that both mutations increase fluconazole resistance, but the specific contribution of these mutations to triazole resistance in C. auris has not been defined (14).”
From Delineation of the Direct Contribution of Candida auris ERG11 Mutations to Clinical Triazole Resistance (2021) · cites this paper as [14]
In the citing paper
“In C. auris, studies have suggested that point mutations in ERG11 contribute to azole resistance of clinical isolates (15).”
From Genetic Analysis of Candida auris Implicates Hsp90 in Morphogenesis and Azole Tolerance and Cdr1 in Azole Resistance (2019) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 7×
“auris is divided into four major clades: South Asian, East Asian, South African, and South American (1).”
BackgroundSelf-citationMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647 · cited 2×
“03 India (1) Y132F 64 to 128 ( 128) 4 to 16 (4) India (22) K143R 64 to 128 ( 128) 0.”
BackgroundSelf-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 3×
“Notably, a wild-type ERG11 genotype was reported in 4 of 5 isolates exhibiting low fluconazole MICs (1 to 2 g/ml) (6).”
BackgroundResultSelf-citationSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Muñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458
Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294
Morio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.11.006 · Cited by 279
Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris
Rhodes, J., Abdolrasouli, A., Farrer, R. A., Cuomo, C. A., Aanensen, D. M., Armstrong-James, D., Fisher, M. C., & Schelenz, S. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0045-x · Cited by 246 · cited 3×
“auris-related infections in other parts of the world, such as the United States or United Kingdom, have been caused by strains that are genetically related to these clades (2, 3).”
BackgroundSagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans
Xiang, M.-J., Liu, J.-Y., Ni, P.-H., Wang, S., Shi, C., Wei, B., Ni, Y.-X., & Ge, H.-L. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12042 · Cited by 197
Research works printed but not linked: 1
- Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts—4th ed. CLSI document M27. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Items 101–166 of 166
Zhang, H., Niu, Y., Tan, J., Liu, W., Sun, M.-A., Yang, E., Wang, Q., Li, R., Wang, Y., & Liu, W. Y. (2019) · mSystems · doi:10.1128/msystems.00459-19 · Cited by 15
“auris could confer triazole resistance (24).”
Hong, H., Ximing, Y., Jinghan, M., Al-Danakh, A., Shujuan, P., Ying, L., Yang, Y., Yuehong, L., & Xingwei, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1211626 · Cited by 18
Mesquida, A., Alcoceba, E., Padilla, E., Ramírez, A., Merino, P., González‐Romo, F., Carolis, E. D., Sanguinetti, M., Mantecón‐Vallejo, M. D. L. Á., Muñoz‐Algarra, M., et al. (2024) · Mycoses · doi:10.1111/myc.13706 · Cited by 17
Exploration of novel mechanisms of azole resistance in Candida auris
Li, J., Brandalise, D., Coste, A. T., Sanglard, D., & Lamoth, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01265-24 · Cited by 19
“The K143R variant has been reported among clinical C. auris isolates, and its role in azole resistance has been demonstrated (5, 15, 16, 20).”
Lanna, M., Lovatto, J. E., de Almeida, J. N., Medeiros, E. A., Colombo, A. L., & García‐Effrón, G. (2025) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2025.101546 · Cited by 16
Liu, Z., Yang, H., Huang, R., Li, X., Sun, T., & Zhu, L. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00284-24 · Cited by 23
“Current evidence links this resistance to the overexpression of ABC1 (141) and a low-affinity form of Erg11 (142, 143).”
Genetic Evaluation of Nosocomial Candida auris Transmission
Roberts, S. C., Zembower, T. R., Ozer, E. A., & Qi, C. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02252-20 · Cited by 15
“auris can occur through variations in the ERG11 gene, such as Y132F and K143R, it is possible that a single SNV in this gene could have led to resistance the ACL isolates (10, 18).”
BackgroundPsychogenetic, genetic and epigenetic mechanisms in Candida auris: Role in drug resistance
Rabaan, A. A., Eljaaly, K., Alfouzan, W. A., Mutair, A. A., Alhumaid, S., Alfaraj, A. H., Aldawood, Y., Alsaleh, A. A., Albayat, H., Azmi, R. A., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.012 · Cited by 14
Hartuis, S., Ourliac‐Garnier, I., Robert, E., Albassier, M., Duchesne, L., Beaufils, C., Kuhn, J., Pape, P. L., & Morio, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00022-24 · Cited by 26
“However, only Y132F conferred cross-resistance to voricona zole, as previously observed in Candida auris (32).”
BackgroundHirayama, T., Miyazaki, T., Tanaka, R., Kitahori, N., Yoshida, M., Takeda, K., Ide, S., Iwanaga, N., Tashiro, M., Takazono, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01508-24 · Cited by 15
“The main mechanism for acquiring resistance is thought to be mutation or overexpression of ERG11 , which encodes lanosterol 14-α-demethylase (24, 25), as well as activation of the efflux pumps Cdr1 and Mdr1 (26).”
Candida auris Resistance Mechanisms to Amphotericin B Alternative Treatments Development
Fenton, A., & John, G. K. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00233-w · Cited by 14
Steinmann, J., Schrauzer, T., Kirchhoff, L., Meis, J. F. G. M., & Rath, P. (2021) · Journal of Fungi · doi:10.3390/jof7050380 · Cited by 13
Zheng, M., Zhou, X., Pang, J., Yang, Z., Zou, Y., Zhang, L., Xu, Y., & Yin, R. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00974-8 · Cited by 11
Casimiro-Ramos, A., Bautista-Crescencio, C., Vidal-Montiel, A., González, G. M., Hernández-García, J. A., Hernández-Rodríguez, C., & Villa‐Tanaca, L. (2024) · Journal of Fungi · doi:10.3390/jof10060392 · Cited by 12
“This substitution is linked to the elevated MICs of azoles [3,34].”
BackgroundZhang, Y., Han, J., Ma, Y., Zhang, F., Li, C., Zhao, J., Lu, B., & Cao, B. (2024) · Infection · doi:10.1007/s15010-024-02378-8 · Cited by 11
“In this study, the substitution in ERG11 (Y132F) was responsible for FCZ resistance, which has been demonstrated in a previous study [32].”
Candida auris ve Antifungal İlaçlara Direnç Mekanizmaları
Alp, Ş., & Arıkan-Akdağlı, S. (2021) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20217 · Cited by 14
Clorgyline Analogs Synergize with Azoles against Drug Efflux in Candida auris
Toepfer, S., Lackner, M., Keniya, M. V., Zenz, L.-M., Friemert, M., Bracher, F., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9060663 · Cited by 11
Carvajal, S. K., Melendres, J., Escandón, P., & Firacative, C. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01403-23 · Cited by 9
Candida auris: un agente patógeno global que se ha arraigado en Colombia
Escandón, P., Lockhart, S. R., Chow, N. A., & Chiller, T. M. (2023) · Biomédica · doi:10.7705/biomedica.7082 · Cited by 11
“The fluconazole-resistance mechanism of Colombian isolates is predominantly the amino acid change in the ERG11 gene at either Y132F or K143R, similar to that of clade 1 isolates (11,40,41).”
ResultTranscriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl
Biermann, A. R., & Hogan, D. A. (2022) · mSphere · doi:10.1128/msphere.00124-22 · Cited by 9
Kordalewska, M., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Garcia‐Rubio, R., Berrío, I., Gardam, D. J., Heath, C. H., Chowdhary, A., Govender, N. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.22.465535 · Cited by 9
“57 In contrast to relatively well-studied mechanisms of azole and echinocandin resistance (10-16), 58 information about C.”
BackgroundSelf-citationYang, B., Vaisvil, B., Schmitt, D. P., Collins, J., Young, E. M., Kapatral, V., & Rao, R. P. (2024) · Infection and Immunity · doi:10.1128/iai.00103-24 · Cited by 9
“After administration of amphotericin B to C. auris , one strain showed induced expression of five genes that are involved in the ergosterol biosynthesis pathway ( MVD , ERG2 , ERG1 , ERG6, and ERG13 ) (16).”
BackgroundDeciphering the multidrug resistance paradigm in Candida auris
Santana, D. J., Cauldron, N. C., Rogers, P. D., & Cuomo, C. A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01062-24 · Cited by 10
“In contrast, two other mutations found in resistant C. auris isolates—I466M and Y501H—had no influence on fluconazole or voriconazole MIC when expressed in S. cerevisiae (53).”
Bohner, F., Papp, C., Takács, T., Varga, M., Szekeres, A., Nosanchuk, J. D., Vágvölgyi, C., Tóth, R., & Gácser, A. (2023) · Journal of Fungi · doi:10.3390/jof9121148 · Cited by 10
“These mechanisms include (i) amino acid substitutions in drug target enzymes (e.g., Erg11) [6,28,29]; (ii) increased drug target production due to the corresponding genomic site’s duplication event (e.g., ERG11) [30,31]; (iii) point mutations in target associated genes (e.g., ERG3 ); or (iv)…”
BackgroundA study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand
Opassathian, K., Boonmee, N., Swangkaew, S., Jenjaroenpun, P., Wongsurawat, T., Kruasuwan, W., Ngamskulrungroj, P., & Mitrpant, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-25386-6 · Cited by 9
Infection caused by Candida auris: state of the art
Marena, G. D., Carvalho, G. C., Monazzi, L., Maschio-Lima, T., Almeida, M. D., Silva, J. D., Fortunato, G., Araújo, V., Venancio, D. C. V., Chang, M., et al. (2022) · Mycosphere · doi:10.5943/mycosphere/13/1/10 · Cited by 6
Diagnostics for human pathogenic fungal infections: Current status and future prospects
Huang, X., Moses, M., Nie, L., Wandera, E. A., & Chen, C. (2026) · hLife · doi:10.1016/j.hlife.2025.11.005 · Cited by 5
“For azoles, mutations in the lan-osterol 14 α -demethylase ( ERG11 in yeast and cyp51 in A. fumigatus ), the primary target enzyme of this drug class, markedly reduce drug binding, thereby diminishing drug efficacy [140–143].”
The emerging pathogen Candida auris: host interactions and disease drivers
Sanya, D. R. A., Arevalo, A. V., Onésime, D., & Nobile, C. J. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01230-5 · Cited by 6
“Azole resistance commonly arises from mutations in ERG11 (e.g., Y132F and K143R) [79] and in TAC1B , which encodes a zinc-cluster transcription factor regulating drug efflux [80].”
Barough, R. E., Abastabar, M., Moazeni, M., Javidnia, J., Valadan, R., Bandegani, A., Nosratabadi, M., Haghani, I., Spruijtenburg, B., Armstrong-James, D. P. H., et al. (2025) · Mycopathologia · doi:10.1007/s11046-025-00945-7 · Cited by 5
“This specific substitution has been documented to play a critical role in conferring resistance to fluconazole, as noted by Healey and Chowdhary et al. [26, 27]].”
Nahiduzzaman, F., Akhi, M. A. J., Zarin, T., Chouhan, C. S., Rahman, M. A., Rahman, A. K. M. A., Khatun, M. M., Islam, M. A., Danishuddin, & Haque, M. A. (2026) · Environmental Reviews · doi:10.1139/er-2025-0165 · Cited by 6
Crystal structure of dihydrofolate reductase from the emerging pathogenic fungus Candida auris
Kirkman, T., Sketcher, A., Barroso, V. D. M., Ishida, K., Tosin, M., & Dias, M. V. B. (2023) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798323004709 · Cited by 4
Rao, R. S. P., Pinto, L., Suravajhala, R., Shenoy, B. D., Sashindran, V. K., & Ghate, S. D. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2479847 · Cited by 4
“The Y132F substitution has been shown to impart a MIC of 64 to > 128 m g/mL for fluconazole and 4 to > 16 m g/mL for voriconazole in C. auris isolates (Healey et al., 2018).”
Vaccaro, A., Cooper, J. F., Rodríguez, A. V., Badali, H., Kean, R., Ramage, G., & Lopez-Ribot, J. L. (2026) · Journal of Fungi · doi:10.3390/jof12040247 · Cited by 4
“Since C. albicans notably exhibits amino acid substitutions in ERG2 , ERG3 , ERG5 , ERG6, and ERG13 that can alter sterol composition in response to polyenes, it is hypothesized that C. auris may employ a similar mechanism, but further studies are required [112,113].”
Bioactive Potential of Streptomyces Spp. Against Diverse Pathogenic Fungi
Harsha, H., Kumar, M., Kumar, P., Solanki, R., & Kapur, M. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_21 · Cited by 3
Reedy, J. M., Fernando, T., Awuor, S. O., Omwenga, E. O., Koutchma, T., & Mariita, R. M. (2024) · Hygiene · doi:10.3390/hygiene4030030 · Cited by 4
Revisiting threats associated with neglected and emerging fungal pathogens in sub-Saharan Africa
Akinola, S. A., Adeyemo, R. O., Bale, M. I., Eilu, E., Afodun, A. M., Akinola, R. A. A., Binuyo, M. O., Odoma, S., Suleiman, I. E., Adegboyega, T. T., et al. (2024) · Discover Public Health · doi:10.1186/s12982-024-00318-3 · Cited by 4
“This assertion offers value as a potential resistant molecular marker for isolates belonging to a particular clade [191].”
Azole resistance: patterns of amino acid substitutions in Candida sterol 14α-demethylase
Rao, R. S. P., Pinto, L., Shastry, R. P., Dakal, T. C., Suravajhala, P., Sashindran, V. K., & Ghate, S. D. (2025) · Antonie van Leeuwenhoek · doi:10.1007/s10482-025-02080-1 · Cited by 4
“%) had multiple types of substitutions – for example, Y132 had three (Y132C, Y132F, and Y132H) and K143 had four (K143E, K143N, K143Q, and K143R) types (Table 2). α Altogether there were 169 known substitutions at 133 sites in sterol 14 -demethylases of seven Candida species (Table 1).”
InfluentialAntifungal-Loaded Calcium Sulfate Beads as a Potential Therapeutic in Combating Candida auris
Butcher, M. C., Brown, J. L., Hansom, D., Os, R. W.-V., Delury, C. P., Laycock, P. A., & Ramage, G. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01713-21 · Cited by 4
“, CDR1) serve to increase FLZ tolerance (15, 16).”
Backgroundde Almeida, J. N., Jiménez‐Ortigosa, C., Francisco, E. C., Colombo, A. L., & Perlin, D. S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01101-22 · Cited by 3
“cloned onto the plasmid pRS416 and transformed into the haploid strain Saccharomyces cerevisiae BY4741 through gap-repair cloning, as previously described (12).”
MethodSelf-citationResistance mechanisms of Cryptococcus spp. and plant compounds as tools to combat them
da Silva, S. P., da Costa, C. B. L., da Silva, J. D. F., Alves, R. R. D. V., Silva, G. A. D. S., de Freitas, A. F. S., Guedes, C. C. D. S., Marinho, A. D. O., Paiva, P. M. G., & Napoleão, T. H. (2021) · Research Society and Development · doi:10.33448/rsd-v10i2.12819 · Cited by 5
“…changes in the drug target and/or implementation of alternative metabolic pathways (Figure 1) (Sionov et al., 2009; Flowers et al., 2012; Lockhart et al., 2017; Healey et al., 2018; Chowdhary et al., 2018; Stone et al., 2019). common mechanism of microbial resistance (Kano et al., 2017).”
BackgroundTomé, L. M. R., Camargo, D. R. A., Bastos, R. W., dos Santos, S. C. F., Guimarães, N. R., Pedroso, S. H. S. P., da Silva, P. E. D. S., Goés‐Neto, A., Figueredo, L. J. D. A., Castro, G. D. C., et al. (2026) · Mycoses · doi:10.1111/myc.70146 · Cited by 3
“Additionally, all Minas Gerais isolates carry amino acid substitutions in the ERG11 gene (K177R, N335S, E343D), consistent with Colombian strains [27].”
Healey, K. R., & Singh, A. K. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3155-3_12 · Cited by 3
Self-citationTracking the origin and evolution of multidrug resistance in Candida auris
Papon, N., & Sanglard, D. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30124-5 · Cited by 2
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Self-citationMemon, S., Ghanchi, N. K., Zafar, U., Farooqi, J. Q., Zaka, S., & Jabeen, K. (2025) · Access Microbiology · doi:10.1099/acmi.0.000952.v6 · Cited by 1
“Triazole resistance associated with ERG11 frequently shows cross-resistance between fluconazole and voriconazole [13].”
Isolation of Fluconazole-Resistant South Asian Clade Candida auris in Beijing, China
Yan, L., Zhao, F., Zhang, K., Wang, P., & Hu, S. (2025) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.24-0748 · Cited by 2
Emergence of Clade III Candida auris of African Origin in Los AngelesPreprint
Price, T. K., Mirasol, R., Ward, K. W., Dayo, A. J., Chandrasekaran, S., Garner, O. B., Maurice, A. D. S., & Yang, S. (2020) · medRxiv · doi:10.1101/2020.10.26.20214908 · Cited by 2
Ceballos-Garzón, A., Peñuela, A., Valderrama, S., Vargas‐Casanova, Y., Ariza, B., & Parra‐Giraldo, C. M. (2022) · medRxiv · doi:10.1101/2022.11.30.22282939 · Cited by 1
Vumbaca, M., Biffignandi, G. B., Cavanna, C., Bellinzona, G., Corbella, M., Cambieri, P., Rhodes, J. L., Corander, J., Baldanti, F., & Sassera, D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.11.622614 · Cited by 1
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Self-citationTomé, L. M. R., Camargo, D. R. A., Bastos, R. W., dos Santos, S. C. F., Guimarães, N. R., Pedroso, S. H. S. P., da Silva, P. E. D. S., Goés‐Neto, A., Figueredo, L. J. D. A., de Castro, G., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.13.627932 · Cited by 1
“Additionally, all genomes analyzed in this study exhibit amino acid substitutions in the ERG11 gene (K177R, N335S, E343D), which is characteristic of Colombian isolates (13).”
Espinel‐Ingroff, A., Sanguinetti, M., & Posteraro, B. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-0336-2
Candida auris: A New, Threatening Yeast
Pemán, J., & Gaitán, A. C. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21000-5
", Vasilyeva, N. V., Taraskina, A. E., Bogomolova, T. S., Vybornova, I. V., Pchelin, I. M., Ryabinin, I. A., Валерьевич, А. Д., Апалько, С. В., Romaniuk, S. A., et al. (2020) · Infectious diseases News Opinions Training · doi:10.33029/2305-3496-2020-9-2-70-76
Transcriptional response of Candida auris to the Mrr1 inducers methylglyoxal and benomylPreprint
Biermann, A. R., & Hogan, D. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.02.482751
Barreto, T. L. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2020.tde-13012022-165803
Retraction: Candida auris: Virulence and antifungal drugs resistance
Al-Garawi, N. A.-H. D., Meri, M. A., & Sahib, R. A. (2023) · AIP conference proceedings · doi:10.1063/5.0181986
RetractedResistome and Resistance Mechanisms of Candidozyma Auris Clade IV: A Systematic Review
Bonilla-Caballero, M. A., Álvarez, G., & González, Á. F. (2025) · Current Tropical Medicine Reports · doi:10.1007/s40475-025-00353-3
“Although resistance to polyenes is less frequent in C. auris , phenotypic resistance to amphotericin B (AmB) and substitutions in the PSK74852 gene (I139T) and FLO8 gene (S108N) have been found in clinical isolates from Colombia [14].”
Cao, J., Wang, X., Qin, C., Gu, D., Zhang, R., Zhou, H., & Li, R. (2026) · Virulence · doi:10.1080/21505594.2026.2667550
“Our SNP analysis revealed strong clade-specific differentiation, with ERG11 Y132F enriched in Clade I and ERG11 VF125AL/F126L characteristic of Clade III iso-lates, consistent with their reported association with reduced azole susceptibility [30,31].”
Antifungal resistance: from classical mechanisms to the expanding role of acetyltransferases
Werneck, S. M. C., Gouveia‐Eufrásio, L., de Freitas, G. J. C., de Carvalho, D. S., César, I. C., Rossato, L. L., Bastos, R. W., Peres, N. T. A., & Santos, D. A. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01273-8
“Mutations in ERG11 have also been associated with reduced azole susceptibility in the emerging multidrug-resistant pathogen C. auris [77–79].”
Saha, P., Debbarma, K., Rathinam, A., Das, S., & Chellam, P. V. (2026) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2026.102877
Osama, D., Alsedawy, M., Hussein, M. S., Hassan, M. A., Elrefaey, S. M., & Tawfick, M. M. (2026) · Antonie van Leeuwenhoek · doi:10.1007/s10482-026-02393-9
“These characteristics suggest that the high-level antifungal resistance observed in C. auris is more likely a recently acquired trait rather than an intrinsic characteristic (Chakrabarti and Sood 2021).”
InfluentialCirculation of fluconazole-resistant Candida auris in Peru confirmed by genomic analysis
Gago, R. P., Núñez-Llanos, A., Céspedes-Román, C., Izarra, V., Hurtado, V., Padilla, C., Cáceres, O., & Lizárraga, W. C. (2026) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760260027
“(53,54) Also, our molecular dicking analysis suggests that the amino acid interaction profile is composed of the residues Gly307, Thr311, Leu376, Arg143, Phe126, Gly303, Thr122, and Ile131 because these interact with fluconazole.”
Resistance gene mutations and phylogenetic relationships in Candidozyma auris isolates from Russia
Oganesyan, E. G., Zhuk, A. S., Gusarova, K. V., Kovyrshin, S., Alekseevskaya, E. S., Orlova, O. E., Khostelidi, S. N., Kozlova, O. P., Любимова, А. В., Taraskina, A. E., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1929119
“In a subsequent global genomic survey of 304 isolates, Y132F was the more widespread variant, detected across 11 countries in approximately 53% of clade I isolates, whereas K143R was concentrated within a speci fi c clade I sublineage and accounted for around 43% of isolates (Chow et al., 2020).”
Influentialde Sousa, D. S. M., Cabral, A. K. L. F., Arantes, B. B. A., Sato, J. H. A., Monari, G. P. D. M., Ruiz, L. D. S., Elgammal, Y., Martinez, L. R., Fusco‐Almeida, A. M., & Mendes‐Giannini, M. J. S. (2026) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2026.2727050
“…skin colonization, and efficient transmission within healthcare settings has established C. auris as one of the most formidable fungal pathogens of the modern era (chowdhary et al. 2017; Berkow and lockhart 2018; Healey et al. 2018; Rhodes et al. 2018; chaabane et al. 2019; escandón et al. 2019).”
Parra‐Giraldo, C. M., Estrada‐Valbuena, J. J., Vargas‐Casanova, Y., Aldea, I., Clemente, L. F., Gil, C., Martínez‐López, R., & Monteoliva, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.19.752827
“In this study, we analysed a clinical isolate (PUJ256) recovered after more than Mutations in ERG11 constitute one of the best-characterized mechanisms of azole resistance in C. albicans (Flowers et al., 2014; Healey et al., 2018).”
Metadata
- Authors
- Healey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrío, I., Chowdhary, A., & Perlin, D. S.
- Affiliations
- Rutgers Health (US)
- Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA
- University of Delhi (IN)
- Municipality of Medellín (CO)
- Corresponding author
- Healey, Kelley R.
- Perlin, David S.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-10
- Volume
- 62
- Issue
- 10
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC6153782
- OpenAlex
- W2886356978
- Cited by
- 165
- References
- 21
- Citations by year
- 2026: 14 · 2025: 9 · 2024: 22 · 2023: 24 · 2022: 18 · 2021: 24 · 2020: 30 · 2019: 21 · 2018: 3
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Greater South Information System
- Funders
- HHS | Centers for Disease Control and Prevention (BAA FY2017-OADS-01)
- Arnold and Mabel Beckman Foundation
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, ERG11, azole resistance, azole susceptibility, amino acid substitutions, minimum inhibitory concentration, heterologous expression, clinical isolates
- MeSH terms
- Antifungal Agents, Azoles, Candida, Cytochrome P-450 Enzyme System, Microbial Sensitivity Tests, Mutation, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.